Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

HCC in the Setting of Hepatitis B: Key Issues for Clinicians Providing Care for Liver Diseases
  • CME

Credits Available
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: March 26, 2021 Expiration: March 25, 2022
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
Gilead Sciences, Inc.
Robert S. Brown, Jr., MD, MPH
Paul Y. Kwo, MD
Norah Terrault Headshot
Norah Terrault, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify individuals with HBV infection who are at high risk for HCC development
  • Apply guideline-based strategies for HCC screening among appropriate patients with HBV infection
  • Develop interdisciplinary strategies for diagnosing and managing HCC in the setting of hepatitis B

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Robert S. Brown, Jr., MD, MPH

Gladys and Roland Harriman Professor of Medicine
Vice Chair,
Mentorship & Academic Development
Clinical Chief, Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Robert S. Brown, Jr., MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb and Gilead Sciences and funds for research support from Gilead Sciences.
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Ambys, Dova, Gilead, Mallinckrodt, Shionogi, and Surrozen; funds for research support from Allergan, Arrowhead, Assembly, Bristol-Myers Squibb, Eiger, Gilead, and Janssen; other financial or material support from Generon and Janssen; and has ownership interest in Durect.
Norah Terrault, MD, MPH

Professor of Medicine
Chief of Gastrointestinal and Liver Diseases
University of Southern California
Los Angeles, California

Norah Terrault, MD, MPH, has disclosed that she has received funds for research support from Gilead, GlaxoSmithKline, and Roche/Genentech.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Jennifer Swanson, PharmD

Editorial Contributor

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, pharmacists, and other healthcare providers caring for patients with or at risk of HCC in the setting of hepatitis B.

Goal

The goal of this activity is to improve clinicians’ understanding of HCC risk in patients with hepatitis B and their competence in HCC screening, diagnosis, and comanagement with oncologists.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-067-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 26, 2021, through March 25, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Introduction: HCC in the Setting of Hepatitis B
  • CME

Loading...
Watch this dynamic panel discussion on HCC risk, screening, surveillance, and management, in the setting of patients with hepatitis B.
Robert S. Brown, Jr., MD, MPH
Paul Y. Kwo, MD
Norah Terrault Headshot
Norah Terrault, MD, MPH
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: March 26, 2021 Expiration: March 25, 2022

This program is divided into several short segments that you can step through using the Video Chapters menu.
PreviousNext

Related Content

下载由专家编写的免费幻灯片,了解亚太地区关于乙型肝炎环境中 HCC 的考虑的最新信息。

Grace LH Wong, 医学博士 Released: June 18, 2021

B 型肝炎の状況における HCC のリスクに関する、アジア太平洋地域における考慮点について、最新情報を得るために、専門家が作成した無料スライドをダウンロード

Grace LH Wong, MDは Released: June 18, 2021

Download free expert-authored slides to get up-to-date on Asia-Pacific considerations regarding HCC in the setting of hepatitis B.

Grace LH Wong, MD Released: June 10, 2021

Clinical Care Options (CCO) expert Dr Grace LH Wong discusses Asia-Pacific considerations in caring for patients with HBV at risk for HCC

Grace LH Wong, MD Released: June 8, 2021

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue